Novavax - excellent results
In a Phase 3 trial in Britain that included 15,000 participants aged 18-84, including 27 percent over the age of 65, efficacy against mild, moderate and severe Covid was 96.4 percent against the original strain.This fell to 89.7 when including people infected with the B.1.1.7 variant, which has been shown to be more transmissible and cause more severe disease.
DJ US travel and tourism sector up,
expedia, booking.com all breaking 5 year highs
US - vaccinations above 10 million jabs
Travel is coming matter of time
Novavax - excellent resultsIn a Phase 3 trial in Britain that...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.58 |
Change
-0.010(0.22%) |
Mkt cap ! $1.654B | |||
| Open | High | Low | Value | Volume |
| $4.59 | $4.61 | $4.55 | $11.40M | 2.486M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1148 | $4.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.61 | 12523 | 3 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| WEB (ASX) Chart |